Abstract:

Aim: Investigation of naturally developed antibodies against SARS-CoV-2 is of great epidemiological importance. In this study, it was aimed to determine the IgG antibody levels against spike protein (S RBD IgG) (S-RDB protein IgG) after two doses of the BNT162b2 vaccine and to compare the antibody response after one dose of vaccine in people who have asymptomatic COVID-19 and after two doses of vaccine in people who have not had COVID-19 before. Method: Blood was drawn from a total of 153 people who were vaccinated with BNT162b2 at XXX State Hospital, with a voluntary consent form, just before the first dose of the vaccine. Two blood samples were taken from 118 individuals who continued the study, 28 days after the first dose of vaccine (just before the second dose of vaccine) and 28 days after the second dose of vaccine. Serum samples were tested with an anti-SARS-CoV-2 Quanti-Vac ELISA IgG kit coated with recombinant S1 antigen to test for SARS-CoV-2 antibodies. Results: When the antibody levels before vaccination are examined; It was determined that 100 patients (65.4%) had negative antibodies, 4 patients (2.6%) had borderline positive and 49 patients (32.0%) had positive antibodies. It was determined that the majority of the side effects after vaccination were in women and participants aged 50-59 years. It was determined that there was no statistically significant difference in terms of 2nd dose antibody levels according to the age classes, gender, BMI levels, occupation, smoking status and concomitant diseases of the patients (p>0.05). In conclusion; more research is needed to determine threshold levels of serum antibodies that could prevent reinfection of SARS‐CoV‐2. Conclusion: more studies are needed to determine whether the antibody titers after vaccination reflect the true protective effect against the virus.

Keywords: